Tests help show whether you have uterine cancer and whether it has spread to other parts of the body. This testing process is called staging and it helps your health care team recommend the best treatment for you.
It is often not possible to work out the stage of uterine cancer until after the examination of any tissue removed during surgery.
Grading describes how the cancer cells look compared to normal cells and helps work out how aggressive the cancer cells may be. This is determined by a pathologist who looks at the biopsy sample under a microscope.
These tables show how endometrial cancers are staged and graded.
Uterine sarcomas are staged differently―to find out more talk to your specialist.
Prognosis means the expected outcome of a disease. You may wish to discuss your prognosis and treatment options with any of your oncologists (gynaecological, radiation or medical). However, it is not possible for any doctor to predict the exact course of the disease in an individual person. Instead, your doctor can give you an idea about the general prognosis for people with the same type and stage of cancer. You will also have tests throughout your treatment that show how well the treatment is working.
Your general practitioner (GP) or gynaecologist will arrange the first tests to assess your symptoms. If you do have uterine cancer you will be referred to a gynaecological oncologist who specialises in treating women with uterine cancer.
The gynaecological oncologist will discuss your test results and treatment options with you, and perform surgery if you need it.
You will be cared for by a range of health professionals who specialise in different aspects of your treatment. This is often referred to as a multidisciplinary team.
This website page was last reviewed and updated July 2018.
Information reviewed by: A/Prof Sam Saidi, Senior Staff Specialist, Gynaecological Oncology Group, Chris O’Brien Lifehouse, NSW; Lauren Atkins, Accredited Practising Dietitian, Peter MacCallum Cancer Centre, VIC; Dr Scott Carruthers, Radiation Oncologist, Royal Adelaide Hospital, SA; Prof Michael Friedlander, Medical Oncologist, Royal Hospital for Women Sydney, NSW; Roslyn McAullay, Social Worker, Women and Newborn Health Service, King Edward Memorial Hospital, WA; Anne Mellon, Clinical Nurse Consultant, Hunter New England Centre for Gynaecological Cancer, NSW; Christine O’Bryan, Consumer; Deb Roffe, 13 11 20 Consultant, Cancer Council SA; Department of Physiotherapy, King Edward Memorial Hospital for Women, WA.